AbbVie is engaged in talks to acquire Gilgamesh Pharmaceuticals, a privately held company specializing in mental health therapeutics, in a deal valued at approximately $1 billion. The potential acquisition reflects growing interest in the mental health and psychedelics sector within the pharmaceutical industry. AbbVie previously collaborated with Gilgamesh and is now considering purchasing the biotech firm outright. This move is viewed by market observers as part of a broader momentum for mergers and acquisitions in the psychedelics space. The discussions were reported by Bloomberg News, citing sources familiar with the matter.